These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 34391699)

  • 1. Precision therapy for RET-altered cancers with RET inhibitors.
    Thein KZ; Velcheti V; Mooers BHM; Wu J; Subbiah V
    Trends Cancer; 2021 Dec; 7(12):1074-1088. PubMed ID: 34391699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precious Gene: The Application of RET-Altered Inhibitors.
    Gou Q; Gan X; Li L; Gou Q; Zhang T
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36557971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision Targeted Therapy with BLU-667 for
    Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
    Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RET fusions in solid tumors.
    Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
    Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress and challenges in RET-targeted cancer therapy.
    Hu X; Khatri U; Shen T; Wu J
    Front Med; 2023 Apr; 17(2):207-219. PubMed ID: 37131086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
    Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
    Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
    Subbiah V; Shen T; Terzyan SS; Liu X; Hu X; Patel KP; Hu M; Cabanillas M; Behrang A; Meric-Bernstam F; Vo PTT; Mooers BHM; Wu J
    Ann Oncol; 2021 Feb; 32(2):261-268. PubMed ID: 33161056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive molecular pathology in metastatic thyroid cancer: the role of
    Nacchio M; Pisapia P; Pepe F; Russo G; Vigliar E; Porcelli T; Luongo C; Iaccarino A; Pagni F; Salvatore D; Troncone G; Malapelle U; Bellevicine C
    Expert Rev Endocrinol Metab; 2022 Mar; 17(2):167-178. PubMed ID: 35404189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.
    Hamidi S; Hu MI
    Ann Endocrinol (Paris); 2024 Apr; 85(2):118-126. PubMed ID: 38342224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.
    Zheng H; Chen ZS; Li J
    Drugs Today (Barc); 2021 Oct; 57(10):621-629. PubMed ID: 34713870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.
    Servetto A; Esposito D; Ferrara R; Signorelli D; Belli S; Napolitano F; Santaniello A; Ciciola P; Formisano L; Bianco R
    Biochim Biophys Acta Rev Cancer; 2022 Nov; 1877(6):188810. PubMed ID: 36202311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic strategies in RET gene rearranged non-small cell lung cancer.
    Drusbosky LM; Rodriguez E; Dawar R; Ikpeazu CV
    J Hematol Oncol; 2021 Mar; 14(1):50. PubMed ID: 33771190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present).
    Acharya B; Frett B
    Expert Opin Ther Pat; 2022 Oct; 32(10):1067-1077. PubMed ID: 36198171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective RET kinase inhibition for patients with RET-altered cancers.
    Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
    Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives.
    Addeo A; Miranda-Morales E; den Hollander P; Friedlaender A; O Sintim H; Wu J; Mani SA; Subbiah V
    Pharmacol Ther; 2023 Feb; 242():108344. PubMed ID: 36632846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting RET alterations in non-small cell lung cancer.
    Nishikawa G; Klein MA
    Curr Probl Cancer; 2024 Apr; 49():101074. PubMed ID: 38494387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
    Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
    J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.
    Wang ZX; Li QQ; Cai J; Wu JZ; Wang JJ; Zhang MY; Wang QX; Tong ZJ; Yang J; Wei TH; Zhou Y; Dai WC; Ding N; Leng XJ; Sun SL; Xue X; Yu YC; Yang Y; Li NG; Shi ZH
    J Med Chem; 2024 Mar; 67(6):4346-4375. PubMed ID: 38484122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hallmarks of RET and Co-occuring Genomic Alterations in
    Adashek JJ; Desai AP; Andreev-Drakhlin AY; Roszik J; Cote GJ; Subbiah V
    Mol Cancer Ther; 2021 Oct; 20(10):1769-1776. PubMed ID: 34493590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
    Sun F; McCoach CE
    Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.